Australian Health Journal met with Commissioner Catherine de Fontenay from the Productivity Commission to discuss the key findings of new research papers, “Advances in Measuring Healthcare Productivity”, released in April and in May, the release of “Making the most of Technology in Healthcare”.
De Fontenay talks about the Commission’s new approach to analysing health productivity, shifting the perspective from the unit measurement of individuals using the health system to the actual improvement of health. This has shown Australia’s health treatment productivity is improving, but identifies gaps in preventative health measures and duplication, where digital technology needs to be more effectively used.
The “Advances in Measuring Healthcare Productivity” research paper emphasises the productivity of healthcare by examining the outcomes of health treatments, such as those for lung cancer, and exploring the possibility of lower-cost settings for treatment, such as home-based care. This approach resulted in a notable 3% increase in productivity annually, showing improved health outcomes and enhanced value for money.
While the research highlights the improving productivity of health treatments, it also emphasises the importance of addressing the factors leading to illness, particularly in light of Australia’s high rates of obesity and alcohol consumption. By tackling these issues, substantial reductions in healthcare costs can be achieved. The research also identifies digital technologies as a promising avenue for cost reduction in healthcare, particularly in minimising excess testing and delivering care in more cost-effective settings.
When accounting for health risks in the population, Australia ranks third among 28 comparable high-income countries in terms of healthcare value for money, indicating the country’s strong performance using this method of measurement.
The second research paper “Making the most of Technology in Healthcare”, underscores the detrimental impact of inadequate electronic medical records on patient care quality, citing preventable medication-related errors costing approximately $1.4 billion annually. Additionally, it emphasises the significance of effective electronic discharge processes from hospitals in reducing the risk of readmission.
The research has advocated for the effective utilisation of digital technologies, including electronic medical records, telehealth, remote care, and artificial intelligence, in the healthcare system. It highlights the potential of these technologies to significantly reduce costs, citing potential savings of about $5 billion for hospitals by reducing test duplication and expediting patient discharge.
Remote monitoring technologies can reduce complications for high-risk diabetes patients, but funding structures need to be improved to maximise their benefits. To that end, the research emphasises the potential of digital technologies to revolutionise the healthcare system, provided that effective utilisation and appropriate funding structures are in place.
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.
Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Understanding factors of persistent lower back pain in women
Lizzy Quinn is a Musculoskeletal Physiotherapist with 20 years experience focusing on people with spinal pain. Australian Health Journal spoke with Lizzy on the complexities of persistent lower back pain in women.
Lower back pain in women in their 30s, 40s, and 50s is complex to treat due to the combination of physical and emotional factors, and health professionals need to stay updated on best practices and science to provide the best recovery platform for patients. These women typically have busy lives, pressures, and expectations.
